Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Repare Therapeutics Inc. (RPTX)

9.7   -0.38 (-3.77%) 03-24 16:00
Open: 9.97 Pre. Close: 10.08
High: 10.2 Low: 9.59
Volume: 78,649 Market Cap: 408(M)

Technical analysis

as of: 2023-03-24 4:29:27 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 12.54     One year: 13.43
Support: Support1: 9.52    Support2: 7.92
Resistance: Resistance1: 10.74    Resistance2: 11.5
Pivot: 10.15
Moving Average: MA(5): 10.13     MA(20): 10.23
MA(100): 13.37     MA(250): 12.84
MACD: MACD(12,26): -0.5     Signal(9): -0.5
Stochastic oscillator: %K(14,3): 31.1     %D(3): 41.4
RSI: RSI(14): 39.7
52-week: High: 18.68  Low: 8.06
Average Vol(K): 3-Month: 142 (K)  10-Days: 109 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ RPTX ] has closed above bottom band by 6.6%. Bollinger Bands are 61.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 10.21 - 10.27 10.27 - 10.31
Low: 9.48 - 9.53 9.53 - 9.57
Close: 9.62 - 9.71 9.71 - 9.77

Company Description

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

Headline News

Tue, 14 Mar 2023
Repare Therapeutics Announces Plenary Oral Presentation at the ... - Business Wire

Fri, 03 Mar 2023
Growth Investors: Industry Analysts Just Upgraded Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts By 31% - Simply Wall St

Wed, 01 Mar 2023
Repare Therapeutics Inc. Misses Q4 EPS by 5c By - UK

Mon, 13 Feb 2023
CHI Advisors Increases Position in Repare Therapeutics (RPTX) - Nasdaq

Wed, 08 Feb 2023
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of ... - Business Wire

Thu, 19 Jan 2023
Repare Therapeutics Receives $1.5 Million (¥200 million) Payment ... - Business Wire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 42 (M)
% Held by Insiders 1.587e+007 (%)
% Held by Institutions 6.2 (%)
Shares Short 773 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -2.701e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) -21.4
Operating Margin (%) -24
Return on Assets (ttm) -5.2
Return on Equity (ttm) -9.9
Qtrly Rev. Growth 40
Gross Profit (p.s.) 19190
Sales Per Share 6.0255e+009
EBITDA (p.s.) -4.0125e+009
Qtrly Earnings Growth -2.6
Operating Cash Flow 0 (M)
Levered Free Cash Flow 9 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0.03

Stock Dividends

Dividend 0
Forward Dividend 1.55e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.